Table II.
TRIM28 expression | |||||
---|---|---|---|---|---|
Clinicopathological characteristic | Number of patients | High | Low | Pearson's χ2 value | P-value |
Age (years old) | 5.797 | 0.016 | |||
≤50 | 27 | 4 | 23 | ||
>50 | 77 | 31 | 46 | ||
ER expression status | 1.187 | 0.276 | |||
Positive | 67 | 25 | 42 | ||
Negative | 34 | 9 | 25 | ||
Tumor size (cm) | 2.813 | 0.093 | |||
<2 | 18 | 3 | 15 | ||
≥2 | 86 | 32 | 54 | ||
Elston grade | 3.454 | 0.178 | |||
I | 11 | 3 | 8 | ||
II | 40 | 8 | 32 | ||
III | 53 | 24 | 29 | ||
Lymph node metastasis | 1.734 | 0.188 | |||
Yes | 59 | 23 | 36 | ||
No | 45 | 12 | 33 | ||
Tumor recurrence | 8.122 | 0.004 | |||
Yes | 48 | 23 | 25 | ||
No | 56 | 12 | 44 |
The top 1/3 of patients with the highest TRIM28 expression were defined as the high-expression group and the bottom 2/3 were defined as the low-expression group. P-values were obtained through the Pearson χ2 test for the comparison of the two groups (high vs. low) in different clinicopathological characteristics of patients with BC. ER, estrogen receptor; TRIM28, tripartite motif containing 28.